Skip to main content
Erschienen in: Current Diabetes Reports 10/2014

01.10.2014 | Diabetes and Other Diseases-Emerging Associations (JJ Nolan, Section Editor)

The Epidemiology of Diabetes and Cancer

verfasst von: Bendix Carstensen, Marit Eika Jørgensen, Søren Friis

Erschienen in: Current Diabetes Reports | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

The literature on cancer occurrence in persons with diabetes has almost invariably been concerned with relative measures. In this paper, we briefly review this, but the aim is to quantify the absolute occurrence of diabetes and cancer in the population in order to give a fuller picture, which also includes the competing mortality risk. Overall, we find that some 35 % of the population will have a diagnosis of diabetes in their lifetime, 44 % a diagnosis of cancer, and about 15 % will have both diagnoses. The impact of differing mortality between persons with and without diabetes is illustrated by the fact that a person without diabetes at age 50 has a smaller lifetime risk of cancer than a person aged 50 with diabetes. Thus, the differences in cancer occurrence between persons with and without diabetes are of quantitatively smaller importance than the differences in mortality.
Literatur
1.
Zurück zum Zitat Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2:307–14.PubMedCrossRef Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2:307–14.PubMedCrossRef
2.
Zurück zum Zitat Wideroff L, Gridley G, Mellemkjær L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360–5.PubMedCrossRef Wideroff L, Gridley G, Mellemkjær L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360–5.PubMedCrossRef
3.
Zurück zum Zitat Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160–7.PubMedCrossRef Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160–7.PubMedCrossRef
4.
Zurück zum Zitat Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745–54.PubMedCrossRef Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745–54.PubMedCrossRef
5.
Zurück zum Zitat HM Colhoun the SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755–65.CrossRef HM Colhoun the SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755–65.CrossRef
6.
Zurück zum Zitat Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–77.PubMedCrossRef Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–77.PubMedCrossRef
7.
Zurück zum Zitat Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732–44.PubMedCrossRefPubMedCentral Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732–44.PubMedCrossRefPubMedCentral
8.••
Zurück zum Zitat Andersson C, Vaag A, Selmer C, Schmiegelow M, Sørensen R, Lindhardsen J, et al. Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open 2012; 2(3). The only study which comprises the entire population in evaluation of possible drug effects on cancer occurrence in persons with diabetes, and therefore the only study of drug effects not potentially biased by selection of subgroups of patients. The study only analyses occurrence of all cancers, not specific sites of cancer. It shows that the risk of cancer is elevated shortly after initiation of (any) therapy, but not in the long run. Andersson C, Vaag A, Selmer C, Schmiegelow M, Sørensen R, Lindhardsen J, et al. Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open 2012; 2(3). The only study which comprises the entire population in evaluation of possible drug effects on cancer occurrence in persons with diabetes, and therefore the only study of drug effects not potentially biased by selection of subgroups of patients. The study only analyses occurrence of all cancers, not specific sites of cancer. It shows that the risk of cancer is elevated shortly after initiation of (any) therapy, but not in the long run.
9.•
Zurück zum Zitat Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012;55(4):948–58. The largest study of cancer occurrence among persons with diabetes. The study takes duration of diabetes into account and shows that risk is highest shortly after diagnosis of diabetes. Also includes analysis by cancer site and insulin use.PubMedCrossRef Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012;55(4):948–58. The largest study of cancer occurrence among persons with diabetes. The study takes duration of diabetes into account and shows that risk is highest shortly after diagnosis of diabetes. Also includes analysis by cancer site and insulin use.PubMedCrossRef
10.•
Zurück zum Zitat Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54:2263–71. The first study to systematically include duration of diabetes as an important determinant of the cancer risk among persons with diabetes. Shows that the risk of cancer is highest shortly after diagnosis of cancer, and inversely related to frequency of GP contact before diabetes diagnosis.PubMedCrossRef Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54:2263–71. The first study to systematically include duration of diabetes as an important determinant of the cancer risk among persons with diabetes. Shows that the risk of cancer is highest shortly after diagnosis of cancer, and inversely related to frequency of GP contact before diabetes diagnosis.PubMedCrossRef
11.
Zurück zum Zitat Ranc K, Jørgensen ME, Friis S, Carstensen B. Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia. 2014;57(5):927–34.PubMedCrossRef Ranc K, Jørgensen ME, Friis S, Carstensen B. Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia. 2014;57(5):927–34.PubMedCrossRef
12.
Zurück zum Zitat Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Møller H. The Diabetes and Cancer Research Consortium. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 2012;55(6):1619–32.PubMedCrossRef Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Møller H. The Diabetes and Cancer Research Consortium. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 2012;55(6):1619–32.PubMedCrossRef
13.
Zurück zum Zitat Sasazuki S, Charvat H, Hara A, Wakai K, Nagata C, Nakamura K, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104(11):1499–507.PubMedCrossRef Sasazuki S, Charvat H, Hara A, Wakai K, Nagata C, Nakamura K, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104(11):1499–507.PubMedCrossRef
14.
Zurück zum Zitat Kajüter H, Geier AS, Wellmann I, Krieg V, Fricke R, Heidinger O, et al. Kohortenstudie zur Krebsinzidenz bei Patienten mit Diabetes mellitus Typ 2. Bundesgesundheitsblatt. 2014;57:52–9.CrossRef Kajüter H, Geier AS, Wellmann I, Krieg V, Fricke R, Heidinger O, et al. Kohortenstudie zur Krebsinzidenz bei Patienten mit Diabetes mellitus Typ 2. Bundesgesundheitsblatt. 2014;57:52–9.CrossRef
15.
Zurück zum Zitat Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–64.PubMedCrossRefPubMedCentral Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–64.PubMedCrossRefPubMedCentral
16.
Zurück zum Zitat Carstensen B, Christensen JK, Marcussen MM, Borch-Johnsen K. The national diabetes register. Scand J Public Health. 2011;39(7 suppl):58–61.PubMedCrossRef Carstensen B, Christensen JK, Marcussen MM, Borch-Johnsen K. The national diabetes register. Scand J Public Health. 2011;39(7 suppl):58–61.PubMedCrossRef
17.
Zurück zum Zitat Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K. The Danish national diabetes register: trends in incidence, prevalence and mortality. Diabetologia. 2008;51:2187–219.PubMedCrossRef Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K. The Danish national diabetes register: trends in incidence, prevalence and mortality. Diabetologia. 2008;51:2187–219.PubMedCrossRef
18.
20.
Zurück zum Zitat Carstensen B. Age-period-cohort models for the Lexis diagram (author’s reply). Stat Med. 2007;27:1561–4.CrossRef Carstensen B. Age-period-cohort models for the Lexis diagram (author’s reply). Stat Med. 2007;27:1561–4.CrossRef
21.•
Zurück zum Zitat Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55(6):1607–18. This paper discusses the methodological aspects of epidemiological evaluation of cancer risk in persons with and without diabetes, and proposes guidelines for this type of studies, particularly in relation to possible drug effects.PubMedCrossRef Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55(6):1607–18. This paper discusses the methodological aspects of epidemiological evaluation of cancer risk in persons with and without diabetes, and proposes guidelines for this type of studies, particularly in relation to possible drug effects.PubMedCrossRef
Metadaten
Titel
The Epidemiology of Diabetes and Cancer
verfasst von
Bendix Carstensen
Marit Eika Jørgensen
Søren Friis
Publikationsdatum
01.10.2014
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 10/2014
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0535-8

Weitere Artikel der Ausgabe 10/2014

Current Diabetes Reports 10/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.